Gotrade News - Wall Street analysts lifted price targets across a cluster of biotech and healthcare names this week, signaling a coordinated sell-side rotation. RBC Capital, Stifel, Leerink Partners, and JPMorgan led the synchronized upgrades into a packed summer catalyst calendar.
The cluster lands as desks position ahead of CG Oncology's PIVOT-006 readout and several RAS-program updates due in coming weeks. Buy-side rotation into the beaten-down sector follows months of underperformance versus the broader equity market this year.
Key Takeaways:
- RBC raised Acadia Healthcare to $31 and CG Oncology to $79 on Q1 strength and catalyst optionality.
- Stifel nearly doubled its Tango Therapeutics target to $40 on PRMT5 plus RAS(ON) synergy conviction.
- Leerink lifted Oruka Therapeutics to $120 after Phase 2a psoriasis data supported annual dosing.
Behavioral Health and Oncology Lead the Cluster
According to Insider Monkey, RBC Capital lifted its price target on Acadia Healthcare from $28 to $31 with Outperform reiterated. The firm cited a fundamental beat-and-raise quarter that addressed denial and bad-debt concerns weighing on shares.
Shares of Acadia Healthcare (ACHC) have been one of the best-performing healthcare names year-to-date on reimbursement clarity. Raymond James went further with a Strong Buy upgrade and a $39 target from $25, a 56 percent lift on optimization plan execution.
Acadia's $200 million optimization program at underperforming behavioral health facilities anchors the bull thesis the two firms now share. Two desks raising targets in the same week mirrors the broader cluster dynamic across biotech and healthcare coverage universes.
As reported by Insider Monkey, RBC raised CG Oncology to $79 from $73 ahead of the PIVOT-006 readout. The firm modeled a 40 percent risk reduction and projected 20 percent upside potential into the early June data window.
Bank of America added a parallel note lifting CG Oncology to $84 from $72, citing the stock's 62 percent year-to-date gain. Per Insider Monkey, Stifel reiterated Buy on Tango Therapeutics (TNGX) and raised its target to $40 from $24.
Stifel cited elevated conviction in PRMT5 inhibitor and RAS(ON) inhibitor synergy for treating pancreatic ductal adenocarcinoma in upcoming combination work. Tango's $343.1 million cash position extends operational runway into 2028 and removes near-term dilution risk heading into key combination data.
RAS Thesis and Dermatology Round Out the Move
According to Insider Monkey, Revolution Medicines received an FDA safe-to-proceed letter on May 1 authorizing expanded access for daraxonrasib. The authorization covers previously treated metastatic pancreatic ductal adenocarcinoma, an indication with limited approved second-line options today.
The investigational RAS(ON) inhibitor sits at the center of a broader thesis driving sentiment on Tango, Erasca, and Revolution Medicines across sell-side coverage. Per Insider Monkey, Leerink raised Oruka Therapeutics to $120 from $109 with Outperform maintained.
The revision followed positive interim Phase 2a results announced on April 27 for lead asset ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001 delivered a 63.5 percent PASI 100 response at Week 16 with a favorable safety profile, supporting potential for once-yearly dosing.
According to Insider Monkey, JPMorgan reiterated Overweight on Erasca and recommended buying at current levels. The firm flagged ERAS-0015 as showing safety differentiation potential with promising early efficacy in non-small cell lung cancer treatment.
H.C. Wainwright echoed the bullish stance with a $20 price target, adding another desk to the RAS thesis. Investors seeking adjacent exposure are revisiting Twist Bioscience (TWST) and other tools names that benefit from rising biotech R&D budgets behind the upgrade cluster.
Sources:
- RBC Capital Lifts PT on Acadia Healthcare Company (Insider Monkey)
- RBC Capital Lifts PT on CG Oncology (Insider Monkey)
- Stifel Remains Bullish on Tango Therapeutics (Insider Monkey)
- Leerink Partners Lifts PT on Oruka Therapeutics (Insider Monkey)
- JPMorgan Recommends Buying Erasca Stock at Current Levels (Insider Monkey)
- Revolution Medicines Receives FDA Safe to Proceed Letter for Daraxonrasib (Insider Monkey)
